On September 10, 2018, the ANSM created, for one year, a Temporary Specialized Scientific Committee (CSST) on the evaluation of the relevance and feasibility of making therapeutic cannabis available in France.
The committee held hearings with stakeholders to gather testimonials and views from healthcare professionals and patients on the use of cannabis for therapeutic purposes.
The initial conclusions of the committee's experts, based on all these elements, are published today.
The agency has taken note of the results and will decide in the next few days on the follow-up to this work, in particular on the possible arrangements for making cannabis available for therapeutic purposes in France.
Summary of CSST opinions
The Committee believes, that it is appropriate to authorize the use of cannabis[1] for therapeutic purposes for patients in certain clinical situations andin the event of insufficient relief or poor tolerance of available drug or non-drug therapies (including cannabis- or cannabinoid-based specialties).
This use can be envisaged as a complement to or replacement for certain therapies.
The therapeutic situations selected by the experts for the use of cannabis for medical purposes are as follows:
in pain refractory to accessible therapies (drug or non-drug);
The CSST would like to see a national registry set up to monitor treated patients and assess their benefit/risk profile, as well as regular assessment of adverse effects by pharmacovigilance and addicto-vigilance networks, and the promotion of research.
To ensure that all these proposals are implemented, the experts would like to see a change in legislation.
Furthermore, in view of the health risks involved, the committee excludes the smoked route of administration for therapeutic cannabis. If necessary, it will issue a detailed opinion on the various possible routes of administration.
All these data are the property of SWISS MEDICAL CANNABIS SA. It is protected by the 91/250/EEC and 96/9/EC directives, which grant copyright protection to computer programs and databases respectively. SWISS MEDICAL CANNABIS SA. reserves the right to take legalaction against any copy or reproduction of our information. We also reserve the right to bring an action for damages, in accordance with Article L. 331-1-3 of the CPI, which states that "to determine the damages, the court shall take into consideration the negative economic consequences, including loss of earnings, suffered by the injured party, the profits made by the author of the infringement of rights and the moral prejudice caused to the owner of these rights as a result of the infringement.
newsletter
Receive our latest news, information and promotions on our products.
4 Commentaires sur "ANSM publishes the first conclusions of the CSST" (inFrench)
aumentar el tamano del pene said:
Thanks for some other informative blog. The place else could I get that kind of information written in such a perfect way!
I have a venture that I'm simply now running on, and
I've been on the glance out for such info.
Hello my family member! I wish to say that this post is amazing, great written and include
approximately all significant infos. I'd like to look extra posts like this .
Thanks for some other informative blog. The place else could I get that kind of information written in such a perfect way!
I have a venture that I'm simply now running on, and
I've been on the glance out for such info.
This piece of writing is genuinely a pleasant one it assists new net viewers,
who are wishing in favor of blogging.
Hello my family member! I wish to say that this post is amazing, great written and include
approximately all significant infos. I'd like to look extra posts like this .
They validated the conclusions of the CSST yesterday, Victory!!!